Secukinumab, marketed as Cosentyx, has received approval for multiple indications. It is approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [1]. Additionally, it is approved for active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant of other disease-modifying antirheumatic drugs (DMARDs) [1]. The drug is also indicated for moderate to severe ankylosing spondylitis in adult patients who have responded inadequately to or are intolerant of conventional therapy [1]. Furthermore, secukinumab is approved for moderate to severe active psoriatic arthritis in pediatric patients aged 6 years and older with polyarticular involvement who have responded inadequately to or are intolerant of DMARDs [2].
What other conditions can Cosentyx treat?
Beyond plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, secukinumab has also gained approval for active non-radiographic axial spondyloarthritis with objective signs of inflammation [3].
How does secukinumab work?
Secukinumab is a human monoclonal antibody that selectively targets the interleukin-17A (IL-17A) cytokine [1]. By inhibiting IL-17A, secukinumab is believed to reduce inflammation associated with certain autoimmune diseases [1].
When does the patent for Cosentyx expire?
Patent expiry dates for pharmaceuticals can be complex and may vary by region and specific patent. Information on the patent status and potential expiry dates for secukinumab can be found on resources like DrugPatentWatch.com [4].
Who are the competitors of Cosentyx?
Secukinumab competes in the immunology market with other biologic therapies. Competitors for plaque psoriasis include other IL-17 inhibitors, TNF inhibitors, and IL-23 inhibitors [5]. In psoriatic arthritis and ankylosing spondylitis, it faces competition from similar drug classes [5].
What are the common side effects of secukinumab?
Common side effects reported with secukinumab include upper respiratory tract infections, headache, and nasopharyngitis [1]. Patients may also experience fatigue, dizziness, and gastrointestinal issues [1].
What is the regulatory status of secukinumab outside the US?
Secukinumab has received marketing authorization in numerous countries worldwide. For instance, it is approved by the European Medicines Agency (EMA) for similar indications as those approved by the U.S. Food and Drug Administration (FDA) [6]. Regulatory approvals are often sought in major global markets to ensure broad patient access.
Are there any Black Box Warnings associated with Cosentyx?
Secukinumab carries warnings regarding an increased risk of serious infections and potential for malignancy [1]. Patients treated with secukinumab should be monitored for signs and symptoms of infection and malignancy [1].
What clinical trials support the approval of Cosentyx?
The approvals for secukinumab were based on a robust clinical trial program. For plaque psoriasis, pivotal trials like PHOENIX 1 and PHOENIX 2 demonstrated efficacy and safety [1]. For psoriatic arthritis, trials such as FUTURE 1 and FUTURE 2 were key [1]. The MAXIMIZE study was instrumental in the approval for ankylosing spondylitis [1].
What is the patient perspective on Cosentyx?
Patient-reported outcomes from clinical trials often assess quality of life, symptom control, and treatment satisfaction. Real-world evidence and patient forums may provide further insights into patient experiences with Cosentyx [7].
What are the risks of discontinuing Cosentyx treatment?
Discontinuing secukinumab treatment may lead to a return of disease symptoms and flares. The long-term consequences of interrupting treatment can vary depending on the underlying condition and individual patient factors [1].
How does Cosentyx differ from other IL-17 inhibitors?
While secukinumab is an IL-17A inhibitor, other IL-17 inhibitors may target different isoforms or have slightly different pharmacokinetic profiles. These differences can sometimes lead to variations in efficacy, safety, or dosing schedules [5].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125523s074,125569s004,125570s004lbl.pdf
[2] https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-approval-cosentyx-secukinumab-pediatric-psoriatic-arthritis-indication
[3] https://www.news-medical.net/news/20191024/Novartis-announces-FDA-approval-of-Cosentyx-secukinumab-for-non-radiographic-axial-spondyloarthritis.aspx
[4] https://drugpatentwatch.com/
[5] https://www.globenewswire.com/news-release/2023/05/23/2673531/0/en/Cosentyx-market-share-by-drug-class-molecule-drug-type-and-route-of-administration-2023-2032-insights-into-the-global-biological-disease-modifying-antirheumatic-drugs-b-dmards-market-and-key-players-e.g.-AbbVie-Amgen-Bristol-Myers-Squibb-Eli-Lilly-and-Company-GSK-Janssen-Biologics-B-V-Novartis-Pfizer-Roche-Sanofi-and-Teva.html
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
[7] https://pubmed.ncbi.nlm.nih.gov/31747874/